BU 4601B

Drug Profile

BU 4601B

Latest Information Update: 17 Jan 2008

Price : $50

At a glance

  • Originator Bristol-Myers Squibb
  • Class Anti-inflammatories; Antiasthmatics; Antipsoriatics; Antirheumatics; Small molecules
  • Mechanism of Action 5-lipoxygenase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Asthma; Psoriasis; Rheumatoid arthritis; Ulcerative colitis

Most Recent Events

  • 17 Jan 2008 Discontinued for Ulcerative colitis in USA (unspecified route)
  • 29 May 1995 No-Development-Reported for Psoriasis in USA (unspecified route)
  • 29 May 1995 No-Development-Reported for Ulcerative colitis in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top